Pfizer and Taisho Reach Deal for Schizophrenia Candidate
This article was originally published in PharmAsia News
Executive Summary
Pfizer finalized an agreement with Taisho Pharmaceutical to acquire development and commercialization rights outside Japan for a metabotropic glutamate receptor (mGluR) agonist, which brings the number of schizophrenia candidates in Pfizer's pipeline to six